InvestIdeas

In July, Marker received notice of a $4.2 million grant to support clinical investigation of MT-601 in relapsed/refractory large B-cell lymphoma.

According to InvestingPro, the company holds more cash than debt on its balance sheet and maintains a "FAIR" financial health rating, while analysis suggests the stock appears undervalued at current levels.

H.C. Wainwright expects FDA feedback on the planned pivotal Phase 2b design for MT-601 in diffuse large B-cell lymphoma to emerge in the second half of 2026.

MT-601 is being developed for lymphoma and pancreatic cancer.